Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss - Wharton, S; Calanna, S; Davies, M (Diabetes Obes Metab, 2022)